Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINGFISHER: Brolucizumab vs Aflibercept in Diabetic Macular Edema
NCT03917472Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2019
- Primary completion
- Mar 2021
- Modality
- scFv Fragments, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of brolucizumab in diabetic macular edema (DME) (2 arms), sponsored by Novartis. Primary endpoint: Change From Baseline in Best-corrected Visual Acuity (BCVA) at 52 weeks. Started Jul 2019; status: completed.
02
Drugs
brolucizumab
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03917472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917472.